Last updated on March 2019

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03


Brief description of study

The purpose of this study is to determine the safety and efficacy of NI-03.

Detailed Study Description

The primary objective of the Single-Dose Phase is to assess the pharmacokinetics (PK) and safety of single doses of NI-03 when administered at doses of 100 mg, 200 mg or 300 mg to subjects with pancreatitis.

The primary objective of the Double-Blind Phase of the study is to determine the efficacy, PK and safety of three doses of NI-03 (100 mg, 200 mg and 300 mg) as compared to placebo when administered three times daily (TID) for 28 consecutive days in subjects with chronic pancreatitis.

Clinical Study Identifier: NCT02693093

Contact Investigators or Research Sites near you

Start Over

Stanford University School of Medicine*

Stanford, CA United States
0.23miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.